Document Type
Patent
Publication Date
October 2014
Patent Number
8853149
CPC
C07K 7/06(20130101), A61K 38/00(20130101)
Abstract
Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
Application Number
13/636,010
Recommended Citation
Hazlehurst, Lori; McLaughlin, Mark; Jain, Priyesh; and Dalton, William S., "Integrin interaction inhibitors for the treatment of cancer" (2014). USF Patents. 160.
https://digitalcommons.usf.edu/usf_patents/160
Assignees
H. Lee Moffitt Cancer Center and Research Institute, Inc. University of South Florida
Filing Date
03/21/2011
Primary/U.S. Class
514/11
